ES2093625T3 - Administracion extendida de farmaco de moleculas pequeñas solubles en agua. - Google Patents

Administracion extendida de farmaco de moleculas pequeñas solubles en agua.

Info

Publication number
ES2093625T3
ES2093625T3 ES90116768T ES90116768T ES2093625T3 ES 2093625 T3 ES2093625 T3 ES 2093625T3 ES 90116768 T ES90116768 T ES 90116768T ES 90116768 T ES90116768 T ES 90116768T ES 2093625 T3 ES2093625 T3 ES 2093625T3
Authority
ES
Spain
Prior art keywords
fluid
biologically active
water
polymeric matrix
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90116768T
Other languages
English (en)
Inventor
Bernhard A Dr Sabel
Andrew Freese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Application granted granted Critical
Publication of ES2093625T3 publication Critical patent/ES2093625T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

DISPOSITIVO POLIMERICO QUE LIBERA MATERIALES HIDROSOLUBLES BIOLOGICAMENTE ACTIVOS CON UN PESO MOLECULAR INFERIOR A 1000 DE UNA FORMA CONTROLADA, CONTINUA Y LINEAL DURANTE UN PERIODO EXTENDIDO DE TIEMPO. LAS MATRICES DE POLIMEROS INSOLUBLES PUEDEN DEFINIRSE DE CUALQUIER FORMA, TAMAÑO Y CONTENIDO FARMACOLOGICO. CUANDO SE APLICA AL USO MEDICO, SE USAN LOS POLIMEROS BIOCOMPATIBLES PARA QUE EL DISPOSITIVO SEA IMPLANTABLE. EL DISPOSITIVO SE LLEVA A CABO AL MODIFICAR DISPOSITIVOS ANTERIORES BASADOS EN LA DIFUSION DEL FLUIDO EN UNA MATRIZ POLIMERICA QUE CONTENGA MOLECULAS ACTIVAS BIOLOGICAMENTE DISPERSAS, PARA PRODUCIR UN DISPOSITIVO POLIMERICO QUE PUEDA SITUARSE EN UN ENTORNO DE FLUIDOS, A FIN DE QUE EL FLUIDO SEA ABSORBIDO POR EL DISPOSITIVO Y LAS MOLECULAS DE AGUA SOLUBLE SE DIFUNDAN EN EL ENTORNO DEL FLUIDO, DEJANDO DETRAS DE SI POROS Y CANALES, EN DONDE LA VELOCIDAD DE DIFUSION QUEDA LIMITADA POR UN REVESTIMIENTO IMPERMEABLE SOBRE UNA PORCION DE LA MATRIZ POLIMERICA Y/O AL AJUSTAR LA CARGA DELFARMACO PARA PRODUCIR EL NUMERO Y TAMAÑO DE POROS Y CANALES EN LA SUPERFICIE DE LA MATRIZ POLIMERICA QUE PRODUCE LA VELOCIDAD DESEADA DE LIBERACION DE LAS MOLECULAS BIOLOGICAMENTE ACTIVAS. EL DISPOSITIVO SE CARACTERIZA POR VARIAS CARACTERISTICAS DISTINTIVAS: UN MECANISMO NORMALMENTE ASOCIADO A LA LIBERACION MACROMOLECULAR QUE ES APLICABLE A PEQUEÑAS MOLECULAS HIDROSOLUBLES Y LA LIBERACION LINEAL, CONTROLADA Y DURADERA DE GRANDES CANTIDADES DEL FARMACO.
ES90116768T 1989-09-14 1990-08-31 Administracion extendida de farmaco de moleculas pequeñas solubles en agua. Expired - Lifetime ES2093625T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/407,418 US5114719A (en) 1987-04-29 1989-09-14 Extended drug delivery of small, water-soluble molecules

Publications (1)

Publication Number Publication Date
ES2093625T3 true ES2093625T3 (es) 1997-01-01

Family

ID=23612002

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90116768T Expired - Lifetime ES2093625T3 (es) 1989-09-14 1990-08-31 Administracion extendida de farmaco de moleculas pequeñas solubles en agua.

Country Status (6)

Country Link
US (1) US5114719A (es)
EP (1) EP0417572B1 (es)
AT (1) ATE141047T1 (es)
DE (1) DE69028011T2 (es)
DK (1) DK0417572T3 (es)
ES (1) ES2093625T3 (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601835A (en) * 1987-04-29 1997-02-11 Massachusetts Institute Of Technology Polymeric device for controlled drug delivery to the CNS
CA2082411A1 (en) * 1991-06-28 1992-12-29 Robert D. Rosenberg Localized oligonucleotide therapy
WO1993001286A2 (en) * 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5302397A (en) * 1991-11-19 1994-04-12 Amsden Brian G Polymer-based drug delivery system
EP0572932B1 (en) * 1992-06-02 2000-09-13 C.R. Bard, Inc. Method and implant device for long term delivery of drugs
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5383873A (en) * 1992-12-09 1995-01-24 Regents Of The University Of Minnesota Smooth muscle chemical pacemaker
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US6416714B1 (en) 1995-04-25 2002-07-09 Discovery Partners International, Inc. Remotely programmable matrices with memories
US6017496A (en) 1995-06-07 2000-01-25 Irori Matrices with memories and uses thereof
US6329139B1 (en) 1995-04-25 2001-12-11 Discovery Partners International Automated sorting system for matrices with memory
US6331273B1 (en) 1995-04-25 2001-12-18 Discovery Partners International Remotely programmable matrices with memories
US5751629A (en) * 1995-04-25 1998-05-12 Irori Remotely programmable matrices with memories
US5874214A (en) 1995-04-25 1999-02-23 Irori Remotely programmable matrices with memories
ATE377418T1 (de) 1995-06-07 2007-11-15 Poniard Pharmaceuticals Inc Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
SE9601421D0 (sv) * 1996-04-12 1996-04-12 Astra Ab New composition
EP0951279A1 (en) * 1997-01-10 1999-10-27 Abbott Laboratories Tablet for the controlled release of active agents
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
WO1999055396A1 (en) * 1998-04-27 1999-11-04 Surmodics, Inc. Bioactive agent release coating
US6319510B1 (en) 1999-04-20 2001-11-20 Alayne Yates Gum pad for delivery of medication to mucosal tissues
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
MXPA03001406A (es) 2000-08-15 2004-05-04 Surmodics Inc Matriz de incorporacion de medicamento.
EP1343548B1 (en) * 2000-11-28 2012-03-28 Boston Scientific Limited Method and apparatus for delivery of therapeutic from a delivery matrix
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
AU2002358270A1 (en) * 2001-12-20 2003-07-09 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same
US8133501B2 (en) 2002-02-08 2012-03-13 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled drug delivery
US8685427B2 (en) * 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
CA2487577C (en) * 2002-05-31 2014-11-18 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
US7097850B2 (en) * 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
US20030232087A1 (en) * 2002-06-18 2003-12-18 Lawin Laurie R. Bioactive agent release coating with aromatic poly(meth)acrylates
US8920826B2 (en) * 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
US8105652B2 (en) * 2002-10-24 2012-01-31 Massachusetts Institute Of Technology Methods of making decomposable thin films of polyelectrolytes and uses thereof
US20040111144A1 (en) * 2002-12-06 2004-06-10 Lawin Laurie R. Barriers for polymeric coatings
SI1610791T1 (sl) * 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
US8246974B2 (en) * 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
WO2004098565A2 (en) * 2003-05-02 2004-11-18 Surmodics, Inc. Implantable controlled release bioactive agent delivery device
WO2004110458A1 (en) * 2003-05-16 2004-12-23 Board Of Regents, The University Of Texas System Phenothiazine enantiomers as agents for the prevention of bone loss
US20100285087A1 (en) * 2003-05-16 2010-11-11 The University Of Texas Single phenothiazine enantiomers as agents for the prevention of bone loss
MXPA05012768A (es) * 2003-05-30 2006-02-22 Titan Pharmaceuticals Inc Dispositivo polimerico implantable para liberacion prolongada de nalmefeno.
US20060083772A1 (en) * 2004-04-06 2006-04-20 Dewitt David M Coating compositions for bioactive agents
US20050220841A1 (en) * 2004-04-06 2005-10-06 Dewitt David M Coating compositions for bioactive agents
PT1781264E (pt) * 2004-08-04 2013-10-16 Evonik Corp Métodos para o fabrico de dispositivis de administração e dispositivos para a mesma
WO2008157372A2 (en) 2007-06-14 2008-12-24 Massachusetts Institute Of Technology Self assembled films for protein and drug delivery applications
ES2718612T3 (es) 2007-12-20 2019-07-03 Evonik Corp Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual
WO2010021973A2 (en) * 2008-08-17 2010-02-25 Massachusetts Institute Of Technology Controlled delivery of bioactive agents from decomposable films
KR101914119B1 (ko) 2010-03-16 2018-11-02 타이탄 파머슈티컬즈 인코퍼레이티드 약물 전달용 이종 이식가능 장치
US8476221B2 (en) 2011-03-18 2013-07-02 Halimed Pharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders
WO2013163234A1 (en) 2012-04-23 2013-10-31 Massachusetts Institute Of Technology Stable layer-by-layer coated particles
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
CA2874824C (en) 2012-06-01 2021-10-26 Surmodics, Inc. Apparatus and methods for coating balloon catheters
WO2014134029A1 (en) 2013-02-26 2014-09-04 Massachusetts Institute Of Technology Nucleic acid particles, methods and use thereof
WO2014150074A1 (en) 2013-03-15 2014-09-25 Massachusetts Institute Of Technology Compositions and methods for nucleic acid delivery
WO2015172149A1 (en) 2014-05-09 2015-11-12 Yale University Hyperbranched polyglycerol-coated particles and methods of making and using thereof
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
US9956323B2 (en) 2014-12-18 2018-05-01 Cook Medical Technologies Llc Medical devices for local bioactive delivery
CN105380909B (zh) * 2015-12-25 2018-07-17 武汉回盛生物科技股份有限公司 一种氟苯尼考可溶性粉及其制备方法
US11136597B2 (en) 2016-02-16 2021-10-05 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
CA3014795A1 (en) 2016-02-16 2017-08-24 Yale University Compositions and methods for treatment of cystic fibrosis
KR102272235B1 (ko) 2016-05-12 2021-07-01 머크 샤프 앤드 돔 코포레이션 항바이러스제의 전달을 위한 약물 전달 시스템
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
WO2019089567A1 (en) 2017-10-30 2019-05-09 Massachusetts Institute Of Technology Layer-by-layer nanoparticles for cytokine therapy in cancer treatment
WO2020033951A1 (en) 2018-08-10 2020-02-13 Yale University Compositions and methods for embryonic gene editing in vitro
WO2020081279A1 (en) * 2018-10-17 2020-04-23 Dow Global Technologies Llc A coating composition, a coated fabric, a method of making a coated fabric, and an article made from the coated fabric
WO2020112816A1 (en) 2018-11-29 2020-06-04 Surmodics, Inc. Apparatus and methods for coating medical devices
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
WO2021002984A1 (en) 2019-05-30 2021-01-07 Massachusetts Institute Of Technology Peptide nucleic acid functionalized hydrogel microneedles for sampling and detection of interstitial fluid nucleic acids
US20220372474A1 (en) 2019-06-21 2022-11-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
US20220243211A1 (en) 2019-06-21 2022-08-04 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
US12496357B2 (en) 2019-07-31 2025-12-16 Yale University Compositions and methods for treating sickle cell disease
US10758329B1 (en) 2019-08-20 2020-09-01 Raymond L. Wright, III Hydrating mouth guard
US12496612B2 (en) 2021-01-08 2025-12-16 Surmodics, Inc. Coating application system and methods for coating rotatable medical devices
WO2022261115A1 (en) 2021-06-07 2022-12-15 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
GB202307563D0 (en) 2023-05-19 2023-07-05 Univ King Abdullah Sci & Tech Methods and compositions
WO2025024693A1 (en) 2023-07-25 2025-01-30 Massachusetts Institute Of Technology Compositions and methods for treating fan1 associated trinucleotide repeat expansion disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US153896A (en) * 1874-08-11 Improvement in argand-burners
DE1215291B (de) * 1961-04-07 1966-04-28 Blendax Werke Schneider Co Einrichtung an in Laengsrichtung geteilten, aufklappbaren Giessformen fuer wachsaehnliche Massen
US3518150A (en) * 1966-09-27 1970-06-30 Philip G Patch Devices for bonding thermoplastic filaments
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3625214A (en) * 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US3948254A (en) * 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US4351337A (en) * 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US3851648A (en) * 1973-10-11 1974-12-03 Mead Johnson & Co Zero-order release device
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
US3965255A (en) * 1974-05-01 1976-06-22 E. E. Eljim Ecology Ltd. Controlled drug releasing preparations
US4034758A (en) * 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4391797A (en) * 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4278087A (en) * 1980-04-28 1981-07-14 Alza Corporation Device with integrated operations for controlling release of agent
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPS57130914A (en) * 1981-02-04 1982-08-13 Agency Of Ind Science & Technol Prolongation of activity retention
US4475916A (en) * 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
NL8401912A (nl) * 1984-06-15 1986-01-02 Tno Met aktieve stof beladen biodegradeerbare polymeersubstraten, geschikt voor het gecontroleerd afgeven van de aktieve stof door middel van een membraan.
FR2573307B1 (fr) * 1984-11-22 1988-06-10 Virbac Ctre Rech Biolog Implants anabolisants a liberation prolongee
DE3689650T2 (de) * 1985-12-17 1994-05-26 United States Surgical Corp Bioresorbierbare Polymere von hohem Molekulargewicht und Implantate davon.
US4761289A (en) * 1986-10-10 1988-08-02 International Minerals & Chemical Corp. Sustained release implant and method for preparing same
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
ES2054784T3 (es) * 1987-08-08 1994-08-16 Akzo Nv Un metodo para la fabricacion de un implante.

Also Published As

Publication number Publication date
DE69028011D1 (de) 1996-09-12
DK0417572T3 (da) 1996-09-02
US5114719A (en) 1992-05-19
EP0417572A2 (en) 1991-03-20
ATE141047T1 (de) 1996-08-15
EP0417572A3 (en) 1991-06-12
EP0417572B1 (en) 1996-08-07
DE69028011T2 (de) 1997-01-23

Similar Documents

Publication Publication Date Title
ES2093625T3 (es) Administracion extendida de farmaco de moleculas pequeñas solubles en agua.
IL78895A0 (en) Controlled release delivery system for macromolecular drugs
NO171004C (no) Fremgangsmaate for fremstilling av en utleveringsanordningsom i naervaer av en opploesningsvaeske frigir en biologisk aktiv bestanddel ved en i praksis konstant hastighet under en utvidet tidsperiode
DE3484165D1 (de) Vernetzte poroese polymere fuer eine kontrollierte wirkstoffabgabe.
DE69935605D1 (de) Ladung und abgabe von wasser unlöslicher arzneimittel
HU910707D0 (en) Preparation of regulated emission of active substance and process for manufacturing it
IL110744A0 (en) Sustained release hydrogel system for insoluble drugs and methods for the preparation thereof
GR3006220T3 (es)
NZ235068A (en) Transdermal drug delivery system with the drug dispersed in a pressure sensitive adhesive acrylate polymer
PT92829A (pt) Dispositivo para administracao de medicamentos atraves da pele
NO884474L (no) Implanterbart, biologisk nedbrytbart virkestoff-frigjoeringssystem.
DE69431800D1 (de) Arzneiverabreichungssystem
IL83017A0 (en) Sustained release pharmaceutical compositions in oral dosage form
GR3030732T3 (en) Pharmaceutical compositions including a drug, a cross-linked polymeric substance, an oil, and a surface active agent.
NZ220599A (en) Controlled release oral dosage formulation of carbidopa and levodopa
ATE91622T1 (de) In einer zur erhoehung ihrer loeslichkeitsrate geeigneten form auf polymere substanzen aufgebrachte schwerloesliche arzneistoffe.
EP0325086A3 (en) Novel methods for obtaining therapeutic systems with controlled release of the drug
US4931281A (en) Laminar structure for administering a chemical at a controlled release rate
SE8601563D0 (sv) Matrismaterial, forfarande for framstellning derav och anvendning derav
DE3879545T1 (es)
Chien [34] Microsealed drug delivery systems: Fabrications and performance

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 417572

Country of ref document: ES